MML Investors Services LLC Has $312,000 Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

MML Investors Services LLC grew its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 16.5% during the third quarter, HoldingsChannel.com reports. The firm owned 4,328 shares of the company’s stock after buying an additional 612 shares during the quarter. MML Investors Services LLC’s holdings in Prestige Consumer Healthcare were worth $312,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of PBH. Raymond James & Associates lifted its stake in Prestige Consumer Healthcare by 10.1% in the 2nd quarter. Raymond James & Associates now owns 117,802 shares of the company’s stock valued at $8,111,000 after acquiring an additional 10,823 shares in the last quarter. Bailard Inc. bought a new stake in Prestige Consumer Healthcare during the second quarter worth $213,000. Miller Howard Investments Inc. NY boosted its holdings in shares of Prestige Consumer Healthcare by 2.2% in the 2nd quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock valued at $534,000 after purchasing an additional 165 shares in the last quarter. F M Investments LLC bought a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $11,162,000. Finally, Innealta Capital LLC acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth $119,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson restated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Finally, StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Trading Up 0.2 %

PBH opened at $78.75 on Wednesday. The company’s 50 day moving average price is $79.42 and its two-hundred day moving average price is $73.26. The firm has a market capitalization of $3.89 billion, a price-to-earnings ratio of 19.16, a PEG ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.95 and a fifty-two week high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. The business had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the business posted $1.07 earnings per share. As a group, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 9,885 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the transaction, the senior vice president now owns 18,835 shares in the company, valued at approximately $1,543,904.95. This trade represents a 34.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock valued at $3,187,300 over the last ninety days. 1.60% of the stock is owned by company insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.